Ibex Ltd

IBEX remains in an early Stage 1 consolidation within a long-term uptrend. Price has repaired its 9/21 EMA regime and is range-bound, suggesting cautious accumulation. Medium-term directional bias is modestly bullish, but short-term timing is neutral, warranting deferred execution into pullbacks around EMA support.

• ↑Q3 FY26 revenue $164.4M (+17% YoY); adjusted EPS $0.91 (+11% YoY).
• ↑Health tech vertical revenue +54% YoY drives high margins.
• ↓Capital expenditures rising to $25–30M could pressure margins.